Measurements of tumor size using CT and PET compared to histopathological size in non-small cell lung cancer

Diagnostic and Interventional Radiology

Volumn 19, Issue 4, 2013, Pages 271-278

  Aydin, Funda ^a   Dertsiz, Levent ^a   Budak, Evrim Sürer ^a   Yildiz, Akin ^a   Özbilim, Gülay ^a   Güngör, Firat ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORINE 18; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; ATELECTASIS; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LOBECTOMY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; RETROSPECTIVE STUDY; THREE DIMENSIONAL IMAGING; TUMOR VOLUME;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGING, THREE-DIMENSIONAL; LUNG NEOPLASMS; MALE; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 84879512705     PISSN: 13053825     EISSN: 13053612     Source Type: Journal    
DOI: 10.5152/dir.2013.053     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics 2007. CA Cancer J Clin 2007; 57:43-66. [CrossRef]
2. Rosell R, Felip E, Maestre J, et al. The role of chemotherapy in early non-small-cell lung cancer management. Lung Cancer 2001; 34:63-74. [CrossRef]
3. Rami-Porta R, Ball D, Crowley J, et al. International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007; 2:593-602. [CrossRef]
4. Janssen-Heijnen ML, Schipper RM, Razenberg PP, Crommelin MA, Coebergh JW. Prevalence of comorbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer 1998; 21:105-113. [CrossRef]
5. Macpherson RE, Higgins GS, Murchison JT, et al. Non-small-cell lung cancer dimensions: CT-pathological correlation and interobserver variation. Br J Radiol 2009; 82:421-425. [CrossRef]
6. Rege SD, Hoh CK, Glaspy JA, et al. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. Cancer 1993; 72:82-90. [CrossRef]
7. Nolop KB, Rhodes CG, Brudin LH, et al. Glucose utilization in vivo by human pulmonary neoplasms. Cancer 1987; 60:2682-2689. [CrossRef]
8. Kelly RF, Tran T, Holmstrom A, Murar J, Segurola RJ Jr. Accuracy and cost-effectiveness of 18F-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer. Chest 2004; 125:1413-1423. [CrossRef]
9. Kanzaki R, Higashiyama M, Maeda J, et al. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients. Interact Cardio Vasc Thorac Surg 2010; 10:1009-1014. [CrossRef]
10. Hicks RJ, Kalff V, MacManus MP, et al. 18F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 2001; 42:1596-1604.
11. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004; 231:305-332. [CrossRef]
12. MacManus M, Nestle U, Rosenzweig KE, et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol 2009; 91:85-94. [CrossRef]
13. Chiti A, Kirienko M, Gregoire V. Clinical use of PET-CT data for radiotherapy planning: what are we looking for? Radiother Oncol 2010; 96:277-279. [CrossRef]
14. van Baardwijk A, Bosmans G, Boersma L, et al. PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys 2007; 68:771-778. [CrossRef]
15. Hatt M, Rest CC, Baardwijk AV, Lambin P, Pradier O, Visvikis D. Impact of tumor size and tracer uptake heterogeneity in 18F-FDG PET and CT non-small cell lung cancer tumor delineation. J Nucl Med 2011; 52:1690-1697. [CrossRef]
16. Yu HM, Liu YF, Hou M, Liu J, Li XN, Yu JM. Evaluation of gross tumor size using CT, 18F-FDG PET, integrated 18F-FDG PET/CT and pathological analysis in non-small cell lung cancer. Eur J Radiol 2009; 72:104-113. [CrossRef]
17. Nestle U, Kremp S, Schaefer-Schuler A, et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med 2005; 46:1342-1348.
18. Pawaroo D, Cummings NM, Musonda P, Rintoul RC, Rassl D, Beadsmoore C. Non-small cell lung carcinoma: accuracy of PET/CT in determining the size of T1 and T2 primary tumors. AJR Am J Roentgenol 2011; 196:1176-1181. [CrossRef]
19. Boellaard R, O'Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2009; 37:181-200. [CrossRef]
20. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307-310. [CrossRef]
21. MacManus MP, Wada M, Matthews JP, Ball DL. Characteristics of 49 patients who survived for 5 years following radical radiation therapy for non-small cell lung cancer: the potential for cure. Int J Radiat Oncol Biol Phys 2000; 46:63-69. [CrossRef]
22. McLoud TC, Bourgouin PM, Greenberg RW, et al. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 1992; 182:319-323.
23. Webb WR, Gatsonis C, Zerhouni EA, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology 1991; 178:705-713.
24. Gupta NC, Tamim WJ, Graeber GG, Bishop HA, Hobbs GR. Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. Chest 2001; 120:521-527. [CrossRef]
25. Steinert HC, Hauser M, Allemann F, et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node sampling. Radiology 1997; 202:441-446.
26. Chan R, He Y, Haque A, Zwishenberger J. Computed tomographic-pathologic correlation of gross tumor volume and clinical target volume in non-small cell lung cancer. Arch Pathol Lab Med 2001; 125:1469-1472.
27. Graziano SL. Non-small cell lung cancer: clinical value of new biological predictors. Lung Cancer 1997; 17:37-58. [CrossRef]
28. Biehl KJ, Kong F, Dehdashti F, et al. 18F-FDG PET definition of gross tumour volume for radiotherapy of non-small-cell lung cancer: is a single standardised up-take value threshold appropriate? J Nucl Med 2006; 47:1808-1812.
29. Hong R, Halama J, Bova D, Sethi A, Emami B. Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning. Int J Radiat Oncol Biol Phys 2007; 67:720-726. [CrossRef]
30. Lee SM, Goo JM, Park CM, Lee HJ, Im JG. A new classification of adenocarcinoma: what the radiologists need to know. Diagn Intern Radiol 2012; 18:519-526.
31. Higashi K, Ueda Y, Seki H, et al. Fluorine-18-FDG PET imaging is negative in bronchoalveolar lung carcinoma. J Nucl Med 1998; 39:1016-1020.
32. Heikkila L, Mattila P, Harjula A, Suomalainen RJ, Mattila S. Tumour growth rate and its relationship to prognosis in bronchiolo-alveolar and pulmonary adenocarcinoma. Ann Chir Gynaecol 1985; 74:210-214.
33. Hsu PK, Huang HC, Hsieh CC, et al. Effect of formalin fixation on tumor size determination in stage I non-small cell lung cancer. Ann Thorac Surg 2007; 84:1825-1829. [CrossRef]
34. Brianzoni E, Rossi G, Ancidei S, et al. Radiotherapy planning: PET/CT scanner performances in the definition of gross tumour volume and clinical target volume. Eur J Nucl Med Mol Imaging 2005; 32:1392-1399. [CrossRef]
35. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216. [CrossRef]